drugset
drugset / Trial / NCT02931110

Study of IV CBL0137 in Previously Treated Hematological Subjects

NCT02931110 ↗

Phase 1 Terminated 5 enrolled Incuron
NaSequentialOpen-labelTreatment

Summary

This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV) administered CBL0137 in participants with previously treated hematological malignancies.

Timeline

Start
2017-01
Primary completion
2020-10
Completion
2020-10

Outcome

Outcome not reported

Stopped (Business): “Business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject CBL0137 Other / unclassified 150 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 180 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 240 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 320 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 400 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 540 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 650 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 780 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 950 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 1150 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 1400 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 1700 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 2000 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 2400 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 2900 mg/m2 Intravenous
Subject CBL0137 Other / unclassified 3500 mg/m2 Intravenous

Indications

hematopoietic and lymphoid cell neoplasm